BioSpace News Archive

Ainos, Inc. announced that it had signed an agreement with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to co-develop a volatile organic compound sensing platform.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer’s Disease (“AD”), achieved positive preclinical end points in a study conducted at Washington University, St. Louis.

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announces, positive reimbursement was received from three commercial payers for the use of the CompuFlo® Epidural System for patients who were involved in motor vehicle accidents.

Omeros Corporation today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023.

TFF Pharmaceuticals, Inc. today announced that it management will host a conference call to discuss the financial results for the second quarter of 2023 and provide an update on recent corporate and clinical developments on Tuesday, August 15, 2023.

China Pharma Holdings, Inc. announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. has received the “Drug Supplementary Application Approval Notice” for its candesartan tablets by National Medical Products Administration of China, indicating that the Company’s candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.

Pharming Group N.V. announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.

Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.

Phonak, a leading global provider of life-changing hearing solutions, is pleased to announce the latest additions to its successful Lumity hearing aid platform.

AlzeCure Pharma AB announced that a new scientific article has been published on the Phase I clinical results supporting the continued development of the lead candidate drug NeuroRestore ACD856.